Eisai-Biogen Alzheimer's therapy to cost 2.98 million yen per year

A single course of treatment with an Alzheimer's drug developed by Japanese company Eisai Co. and U.S. firm Biogen Inc. will cost around 2.98 million yen ($20,500) per year in Japan and will be largely covered by public health insurance, a health ministry body said Wednesday.The highly anticipated drug, lecanemab, will be launched in Japan on Dec. 20, the companies said. The drug won approval in September as the country's first that can slow the progression of the debilitating neurodegenerative disease's symptoms by removing a protein believed to be the cause.As the drug, branded Leqembi, w…READ FULL ARTICLE